BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.39 --0%
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
OMID, ACI, UNH, More
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
OMID, ACI, UNH, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.
BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- JPMorgan Downgrades Localiza Rent a Car S.A. (RENT3:BZ) (LZRFY) to Neutral
- Meta Platforms Inc. (META) PT Raised to $1,000 at Truist Securities
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
